We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Focus on... Posaconazole.
- Authors
Sircar-Ramsewak, Feroza; Kuti, Joseph L.; Nicolau, David P.
- Abstract
Serious fungal infections have emerged as a prominent cause of infectious morbidity and mortality globally. Posaconazole, a novel broad-spectrum triazole antifungal, is currently in clinical development and is undergoing FDA review for the treatment of invasive fungal infections. Posaconazole possesses potent in vitro and in vivo activity against Candida species, Aspergillus species, and other rare and emerging fungal pathogens including Zygomycetes. During clinical trials, posaconazole demonstrated efficacy in immunocompromised patients with invasive infections caused by these fungi that were refractory to standard therapies. If approved, posaconazole will be available as an oral suspension, which, when taken with food, has demonstrated excellent bioavailability. Additionally, posaconazole appears to be safe and well tolerated over prolonged durations of treatment and has a promising drug interaction profile compared to other available azoles. If approved, the eventual cost and further clinical experience with this antifungal will ultimately determine its utility in the treatment of invasive fungal infections. INSET: Formulary considerations.
- Subjects
MYCOSES; INFECTION; ETIOLOGY of diseases; MEDICAL microbiology; CLINICAL medicine; DRUG interactions
- Publication
Formulary, 2005, Vol 40, Issue 1, p13
- ISSN
1082-801X
- Publication type
Article